Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice

被引:25
|
作者
Picchio, GR [1 ]
Gulizia, RJ [1 ]
Mosier, DE [1 ]
机构
[1] SCRIPPS RES INST, DEPT IMMUNOL IMM7, LA JOLLA, CA 92037 USA
关键词
D O I
10.1128/JVI.71.9.7124-7127.1997
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Individuals homozygous for a 32-bp deletion (Delta 32) in the CCR5 gene encoding the coreceptor for macrophage-tropic human immunodeficiency virus type 1 (HIV-1) are resistant to virus infection, and heterozygous individuals show some slowing of disease progression. The impact of the CCR5 genotype on HIV-1 infection was assessed in vitro and in the human PBL-SCID (hu-PBL-SCID) model. Cells and hu-PBL-SCID mice from CCR5 Delta 32/Delta 32 donors were resistant to infection with macrophage-tropic HIV-1 and showed slower replication of dual-tropic HIV-1. hu-PBL-SCID mice derived from CCR5 Delta 32/+ heterozygotes showed delayed replication of macrophage-tropic HIV-1 despite a small and variable effect of heterozygosity on viral replication in vitro, The level of CCR5 expression appears to limit replication of macrophage-tropic and dual-tropic HIV-1 strains in vivo.
引用
收藏
页码:7124 / 7127
页数:4
相关论文
共 50 条
  • [41] CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes
    Arthos, J
    Rubbert, A
    Rabin, RL
    Cicala, C
    Machado, E
    Wildt, K
    Hanbach, M
    Steenbeke, TD
    Swofford, R
    Farber, JM
    Fauci, AS
    JOURNAL OF VIROLOGY, 2000, 74 (14) : 6418 - 6424
  • [42] Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1
    Tuttle, DL
    Harrison, JK
    Anders, C
    Sleasman, JW
    Goodenow, MM
    JOURNAL OF VIROLOGY, 1998, 72 (06) : 4962 - 4969
  • [43] V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1
    Chan, SY
    Speck, RF
    Power, C
    Gaffen, SL
    Chesebro, B
    Goldsmith, MA
    JOURNAL OF VIROLOGY, 1999, 73 (03) : 2350 - 2358
  • [44] The fitness cost to human immunodeficiency virus type 1 of escaping from a small molecule CCR5 inhibitor
    Marozsan, Andre J.
    Matet, Alexandre
    Kuhmann, Shawn E.
    Rivera, Enid
    Morgan, Tom
    Arts, Eric J.
    Moore, John P.
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [45] Regulation of human immunodeficiency virus type 1 infection, β-chemokine production, and CCR5 expression in CD40L-stimulated macrophages:: Immune control of viral entry
    Cotter, RL
    Zheng, JL
    Che, M
    Niemann, D
    Liu, Y
    He, J
    Thomas, E
    Gendelman, HE
    JOURNAL OF VIROLOGY, 2001, 75 (09) : 4308 - 4320
  • [46] CCR5Δ32 protein expression and stability are critical for resistance to human immunodeficiency virus type 1 in vivo
    Agrawal, Lokesh
    Jin, Qingwen
    Altenburg, Jeff
    Meyer, L.
    Tubiana, R.
    Theodorou, Ioannis
    Alkhatib, Ghalib
    JOURNAL OF VIROLOGY, 2007, 81 (15) : 8041 - 8049
  • [47] Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1
    Doranz, BJ
    Lu, ZH
    Rucker, J
    Zhang, TY
    Sharron, M
    Cen, YH
    Wang, ZX
    Guo, HH
    Du, JG
    Accaviti, MA
    Doms, RW
    Peiper, SC
    JOURNAL OF VIROLOGY, 1997, 71 (09) : 6305 - 6314
  • [48] The Fitness Cost to Human Immunodeficiency Virus Type 1 of Escaping From a Small Molecule CCR5 Inhibitor
    Andre J Marozsan
    Alexandre Matet
    Shawn E Kuhmann
    Enid Rivera
    Tom Morgan
    Eric J Arts
    John P Moore
    Retrovirology, 2
  • [49] CCR5 Δ32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1
    Meyer, L
    Magierowska, M
    Hubert, JB
    Mayaux, MJ
    Misrahi, M
    Le Chenadec, J
    Debre, P
    Rouzioux, C
    Delfraissy, JF
    Theodorou, I
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03): : 920 - 924
  • [50] Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
    Maeda, K
    Nakata, H
    Koh, Y
    Miyakawa, T
    Ogata, H
    Takaoka, Y
    Shibayama, S
    Sagawa, K
    Fukushima, D
    Moravek, J
    Koyanagi, Y
    Mitsuya, H
    JOURNAL OF VIROLOGY, 2004, 78 (16) : 8654 - 8662